About us
A history of innovation, access, and empathy
Cavidi was founded in 1984 by two virologists from Uppsala University in Sweden. The company’s initial focus was the application of reverse transcriptase in the in vitro detection of biomarkers for oncology and infectious diseases. Thus the name CAVIDI — CAncer and VIrus DIagnostics. The company succeeded in developing tests that could rival PCR in sensitivity, yet required no specialized equipment or workflows.
In 2020 the team at Cavidi was following the pandemic closely and wanted to help. They felt their expertise in virology, biomarkers, and RT could be relevant to the global crisis.
Cavidi’s research focus shifted to address the global pandemic. Managing the SARS-CoV-2 virus requires an easily deployed diagnostic test. Virologists at Cavidi set out to provide results that could rival the accuracy of PCR without the cost, equipment, or time required to run the test.
What started as the pursuit of a fast, easy, and reliable way to diagnose COVID-19 ended with the discovery of BOLD (Binding Oligo Ladder Detection) — a novel immunoassay signal booster that can be used to increase the sensitivity of virtually any type of immunoassay by a factor of up to 100x with minimal background noise. Branded Exazym®, it was successfully trialed on the SARS-CoV-2 virus and is now being tested on a number of challenging low-abundance biomarkers.
Exazym® is a game-changer in biomarker detection and precision health. It makes highly reliable, incredibly sensitive detection accessible to all researchers globally.
The company is now fully focused on bringing Exazym® and BOLD to a global audience through direct sales of kits and services to researchers as well as forging licensing agreements with research-use-only (RUO) kit providers and partnerships with companies providing various in-vitro diagnostic (IVD) applications for use in hospitals and clinics.
Vision
A world where everyone has access to healthcare that is personalized, preventative, and precise.
Mission
To fuel advancement in healthcare by providing researchers and clinicians with greater access to precision diagnostics.
Goals
Establish Binding Oligo Ladder Detection (BOLD) as the world’s go-to ultra-sensitive ELISA amplification technique by 2030.
Detection democratized
Help amplify our message
Quality diagnostics and monitoring are foundational for good health. However, all too often the “best-in-class” test is too expensive or complicated for many research labs.
The term best-in-class, used to describe today’s diagnostic and monitoring tools, is a myopic accolade. It rightly celebrates the technical accuracy of the test but completely ignores access. We see this level of achievement as the first step. The only tests that ascend to the head of our class are those that offer both high accuracy and widespread access.
Our latest breakthrough is Exazym® — a game-changer in biomarker detection. It makes highly reliable, incredibly sensitive immunoassay signal amplification accessible to all researchers and clinicians globally. This innovation empowers researchers with unparalleled precision in biomarker discovery, detection, and monitoring, laying the foundational stones for the next generation of personalized, predictive, and precision medicine.
Help us democratize detection. Sign up for our mailing list, join us on social media, and spread the word.
Join usCavidi Leadership
15 years with Cavidi. Extensive sales and service experience in international markets with UTC, Volvo, ABB, and Schneider Electric. Proven track record with go-to-market strategies and business development for new disruptive technologies across multiple industries and geographies. B.S. Engr., MBA University of Virginia.
A seasoned C-suite leader with 25+ years in life sciences, specializing in industrial biotechnology, including development, production, and technical sales/marketing. He has led teams and driven results at companies like Millipore, GE Healthcare, Vironova, and Bio-Works Technologies. Jonathan holds a Master’s in chemical engineering from Northeastern University.
20 years leadership experiences within supply chain and QA in Biotech industry. Responsible for build up of a new USD 30M manufacturing plant and start-up of protein production. Worked closely with R&D and product management in many roles at GEHC, mostly with NPI and quality. M.Sc. in Chemical Engineering.
With 10+ years in life sciences quality assurance, Helena brings expertise in regulatory frameworks, validation, and quality control from roles at GE Healthcare, Oasmia, Sysmex Astrego, and OssDsign. She holds a PhD in microbiology and has led projects to enhance quality systems.
Trained accountant and generalist manager with 30 years’ business experience including Communications Manager in the insurance industry, Brand Director for Nordea Bank, Sales and Marketing for an IT consultancy, and most recently, 8 years as a Management Consultant.
With 35+ years of experience in pharma, medtech, and finance, Johan has held executive roles at companies like Pharmacia, GE Healthcare, Arocell, Ratos, Radi Medical, and SEB. He specializes in strategy, commercialization, and business development across various industries.
Co-founded Cavidi Tech AB in 1984. Served as Cavidi’s Director of R&D for 12 years and for 10 years on Cavidi board of directors, having previously served on Cavidi Tech AB’s board. Chairs the Cavidi Scientific Advisory Committee. Associate Professor of Medical Virology at Uppsala University. Author of over 60 published research papers.
Joined Cavidi in 2020 after 20+ years in leading positions in the Pharma industry. Strong scientific background and extensive experience in heading up research teams at international companies such as Eli Lilly and AstraZeneca, and recently, also with startups and biotech companies.
Free consultation for kit providers
Contact us for a no-obligation technical expert consultation to discuss how Exazym® could be integrated into your immunoassay for signal enhancement.
Let's talkKeep in touch
Join our mailing list to receive new information relating to biomarker discovery and detection.